Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Death from the more serious form of the disease is highest among adults 50 and above, Merck said in a release in December. Even after the FDA approval, the company's single-dose vaccine won't ...

The Food and Drug Administration (FDA) has approved pharmaceutical company Merck’s (NYSE:MRK) new vaccine, Capvaxive. This pneumococcal conjugate vaccine is designed to prevent invasive disease ...

A CDC advisory committee will meet June 27 to vote on recommendations for the vaccine. The FDA has approved Merck’s 21-valent pneumococcal vaccine, which is specifically made for adults ...

The Food and Drug Administration approved Merck's Capvaxive, a vaccine to prevent the invasive bacterial infection pneumococcal disease in adults age 50 or older. Merck said that across four Phase ...

For everyone who does not have aichmophilia, the U.S. Food and Drug Administration (FDA) has just approved ... Therefore, Sanofi and Merck, who developed the vaccine in a joint-partnership ...

Monday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.